Comorbidities in patients initiating methotrexate in DMARD monotherapy at RA diagnosis, overall and by serological status
| All RA at diagnosis n=11 001 | Seropositive RA at diagnosis* n=7560 | Seronegative RA at diagnosis* n=3147 | |
| Cardiovascular, n (%) | 942 (8.6) | 575 (7.6) | 336 (10.7) |
| Non-cardiac vascular, n (%) | 3163 (28.8) | 1976 (26.1) | 1093 (34.7) |
| Malignant, n (%) | 467 (4.3) | 283 (3.7) | 167 (5.3) |
| Endocrine, n (%) | 2234 (20.3) | 1506 (19.9) | 664 (21.1) |
| Gastrointestinal, n (%) | 681 (6.2) | 447 (5.9) | 215 (6.8) |
| Infectious, n (%) | 612 (5.6) | 411 (5.4) | 184 (5.9) |
| Chronic kidney disease, n (%) | 61 (0.6) | 37 (0.5) | 23 (0.7) |
| Neurological, n (%) | 770 (7.0) | 495 (6.6) | 258 (8.2) |
| Psychiatric, n (%) | 1660 (15.1) | 1118 (14.8) | 497 (15.8) |
| Respiratory, n (%) | 525 (4.8) | 359 (4.8) | 148 (4.7) |
| No comorbidity, n (%) | 4804 (43.7) | 3473 (45.9) | 1216 (38.6) |
| RDCI: 0, n (%) | 7554 (68.7) | 5355 (70.8) | 2006 (63.7) |
| RDCI: 1, n (%) | 1602 (14.6) | 1039 (13.7) | 520 (16.5) |
| RDCI: 2, n (%) | 825 (7.5) | 526 (7.0) | 271 (8.6) |
| RDCI≥3, n (%) | 1020 (9.3) | 640 (8.5) | 350 (11.1) |
*Missing information on serological status: 294 (2.7%).
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RDCI, Rheumatic Disease Comorbidity Index.